

[Home](#) [Today's Paper](#) [All Sections](#) [News](#) [National](#) [International](#) [Opinion](#) [Business](#) [Sport](#) [E](#)[Cities](#) [Bengaluru](#) [Chennai](#) [Coimbatore](#) [Delhi](#) [Hyderabad](#) [Kochi](#) [Kozhikode](#) [Kolkata](#) [Madurai](#) [Mangaluru](#)**CITIES » HYDERABAD**

HYDERABAD, December 13, 2015

Updated: December 13, 2015 05:42 IST

Advances in personalised medicine discussed

SPECIAL CORRESPONDENT[COMMENT \(1\)](#) · [PRINT](#) · [T](#) [T](#)[f Like](#) [Share](#) [0](#) [t Tweet](#) [G+1](#) [0](#) [in Share](#) [13](#) [+ Share](#)

Chief Scientific Officer on the San Diego-based life sciences company Sequenom Laboratories, Charles Cantor, said various sensitive measures were under experimentation to monitor cancer patients and decide on drug alternates.

He was addressing the gathering at a guest talk on precision medicine and advances in biomarker research in oncology and prenatal segments organised by MedGenome, a major in precision medicine in India, and Imperial Life Sciences. Dr. Cantor discussed various advancements in personalised medicine and how liquor biopsies were being researched to replace conventional chemotherapy and biopsies.

Director-applications of Agena Bioscience, also based in San Diego, Darryl Irwin said technologies were available now that helped in designing content for each patient, enabling personalised medicine.